Arcus Biosciences
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan,...
Latest News
12 days ago · zacks.com
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue EstimatesArcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.27 per share a year ago.
21 days ago · businesswire.com
Arcus Biosciences Announces New Employment Inducement GrantsHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company's common stock at an exercise price per share of $18.54, which was the closing price.
26 days ago · businesswire.com
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti.
26 days ago · businesswire.com
Arcus Biosciences Announces Commencement of Public Offering of Common StockHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase.
27 days ago · seekingalpha.com
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still AheadArcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks, with manageable safety profiles and broad potential across treatment lines. Valuation is rich at 22.5x trailing and 37.9x forward sales, reflecting high pipeline expectations and leaving RCUS vulnerable to clinical setbacks.
27 days ago · seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy TranscriptArcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
28 days ago · zacks.com
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseArcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 months ago · businesswire.com
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of TherapyHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City. The event will highlight new data from the ARC-20 platform study, which is evaluating casdatif.
2 months ago · seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptArcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptArcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RCUS